Massachusetts Life Science Center awards nearly $30 million to 33 life sciences companies
CAMBRIDGE – Today, the Healey-Driscoll Administration and the Massachusetts Life Sciences Center (MLSC) announced $29.9 million in tax incentive awards to 33 life sciences companies. The awards, provided through the MLSC’s Tax Incentive Program, are expected to create 1,519 new life sciences industry jobs in Massachusetts. Governor Maura Healey joined MLSC President and CEO Kirk Taylor, MD, and state and local officials to announce the awards at Lila Sciences in Cambridge.
The Governor also announced a new competitive round of the tax incentive program. To fully maximize the new $40 million statutory cap in the Mass Leads Act, this round seeks to competitively award the remaining $10.1 million available for this year.
“The world looks to Massachusetts for the future of life sciences because we have built an ecosystem where innovative research, exceptional talent and public-private partnerships come together to drive significant progress,” said Governor Maura Healey. “With impactful investments like MLSC’s Tax Incentive Program, we are creating new jobs and ensuring that the next generation of scientific breakthroughs are being developed right here in our state.”
“This year’s tax incentive awardees are advancing scientific innovation, strengthening our economy and improving lives across the globe with groundbreaking work,” said Lieutenant Governor Kim Driscoll. “Their successes are a shining example of why Massachusetts continues to lead the nation in life sciences.”
The MLSC Tax Incentive Program is offered to companies engaged in life sciences research and development, commercialization and manufacturing in Massachusetts, and provides incentives to companies of all sizes looking to expand their efforts by creating new, long-term jobs in the state.
“It is more important than ever for Massachusetts to support the life sciences ecosystem,” said Interim Economic Development Secretary Ashley Stolba, who serves as Co-Chair of the MLSC’s Board of Directors. “In this state, we’re committed to ensuring that companies looking to expand have access to our top talent, and the tax incentive program is an important tool allowing us to continue to grow our ecosystem. The Mass Leads Act sharpened this tool and elevated its competitiveness.”
“Growing Massachusetts’ life sciences companies directly benefits our state’s workforce and economy,” said Administration and Finance Secretary Matthew J. Gorzkowicz, who serves as Co-Chair of the MLSC’s Board of Directors. “This commitment keeps Massachusetts competitive and allows our communities to thrive.”
Out of the 33 companies receiving tax incentive awards, 18 companies, accounting for 48 percent of the new jobs, are expanding in communities outside of Boston and Cambridge. Through this program, life sciences companies have committed to the creation of more than 19,800 jobs since the MLSC’s inception.
“Supporting job creation at innovative companies of all sizes is vital to strengthening Massachusetts’ position as the nation’s leader in life sciences,” said MLSC President and CEO Kirk Taylor, M.D. “The commitment of this year’s awardees is an inspiring demonstration of the Commonwealth’s shared dedication to advancing groundbreaking research and improving patients’ lives across the globe.”
“We are fortunate to be able to attract many of the brightest minds in AI and science on our mission to build scientific superintelligence,” said Geoffrey von Maltzahn, Ph.D., Co-Founder and Chief Executive Officer of Lila Sciences and General Partner, Flagship Pioneering. “Our commitment to add at least 100 new jobs here in Massachusetts is just the start. The MLSC’s support fuels continued momentum as Lila Sciences aims to transform R&D with an AI-first approach to life, chemistry, and materials science innovation.”
Last November, Governor Maura Healey signed the Mass Leads Act, an economic development bill building on the success of the state’s renowned life sciences sector. The legislation increased the statutory cap from $30 million to $40 million for life sciences tax incentives and made targeted reforms to strengthen the program.
The application period for the new MLSC Tax Incentive cycle opens today June 12, 2025, and will close at 5 p.m. on July 16, 2025. Similar to the first round, the awards will be for net new jobs created during calendar year 2025. The second cycle of the MLSC Tax Incentive program will run with the same criteria as the first cycle. Exact details of the program can be found in the updated solicitation on the MLSC website.
This year’s Tax Incentive Program award recipients represent a diverse cohort of companies working on drug discovery and development, medical devices, diagnostics, and manufacturing.
“The Massachusetts Life Sciences Center’s tax-incentive award is more than a financial boost—it’s a vote of confidence in the bold science happening here in the Commonwealth. For Thymmune, it advances our mission to regenerate the human thymus and deliver first-in-class immune-restorative therapies to patients who have no alternatives today,” said Stan Wang, M.D., Ph.D., Founder & CEO of Thymmune Therapeutics. “We’re grateful to Governor Healey, the MLSC, and the Legislature for investing not only in jobs, but in the people and ideas that keep Massachusetts at the forefront of life-science innovation.”
The recipients include:
| Company | Expansion Location | Incentive Amount | Job Commitment |
| Alnylam Pharmaceuticals Inc. | Norton | $1,840,000 | 100 |
| Argenx Us Inc. | Boston | $1,080,000 | 60 |
| Amplitude Vascular Systems Inc. | Boston | $245,000 | 10 |
| Novo Nordisk/(Dicerna) | Lexington | $900,000 | 50 |
| EyePoint | Northbridge | $365,000 | 15 |
| Fresenius Kabi Compounding LLC (Fagron Sterile) | Canton | $420,000 | 20 |
| GlaxoSmithKline LLC (GSK) | Cambridge | $2,700,000 | 150 |
| Hillstar Bio Inc. | Boston | $115,000 | 5 |
| Werfen | Bedford | $1,675,000 | 85 |
| Insulet Corporation | Acton | $1,524,000 | 83 |
| Integra LifeSciences Corporation | Braintree | $1,997,000 | 89 |
| Invagen Pharmaceuticals Inc., wholly owned subsidiary of Cipla Limited | Fall River | $1,795,000 | 70 |
| Kailera Therapeutics Inc. | Waltham | $900,000 | 50 |
| Lila Sciences Inc. | Cambridge | $1,850,000 | 100 |
| Merida Biosciences Inc. | Cambridge | $388,000 | 16 |
| NanoDx Inc. | Southborough | $168,000 | 6 |
| Nova Biomedical Corporation | Waltham | $1,675,000 | 75 |
| Novartis Institutes for BioMedical Research Inc. | Boston | $1,260,000 | 70 |
| Parabilis Medicines Inc. | Cambridge | $272,000 | 14 |
| PathAI Inc. | Boston | $180,000 | 10 |
| QurAlis Corporation | Cambridge | $118,000 | 6 |
| Ratio Therapeutics Inc. | Boston | $306,000 | 17 |
| Remix Therapeutics Inc. | Watertown | $180,000 | 10 |
| RevBio Inc. | Lowell | $150,000 | 5 |
| Sharp Sterile Manufacturing LLC | Lee | $125,000 | 5 |
| STC Biologics Inc. | Newton | $186,000 | 7 |
| Superluminal Medicines Inc. | Boston | $437,000 | 19 |
| Thymmune Therapeutics Inc. | Cambridge | $135,000 | 5 |
| Topo Therapeutics Inc. | Watertown | $161,000 | 7 |
| Tscan Therapeutics Inc. | Waltham | $470,000 | 25 |
| Vertex Pharmaceuticals Inc. | Boston | $5,610,000 | 300 |
| Viridian Therapeutics Inc. | Waltham | $465,000 | 25 |
| ZOLL Medical Corporation | Chelmsford | $210,000 | 10 |
The MLSC jointly administers the Tax Incentive Program with the Massachusetts Department of Revenue, which oversees the technical administration of the incentives. Awardees are required to maintain job commitments over a three-year period. The program includes regular reporting requirements for awardees to document jobs created as a result of the incentive. The MLSC has continued to use the Tax Incentive Program to leverage diverse life sciences assets across Massachusetts and encourage growth, expansion, and retention on a statewide basis.
About the Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center (MLSC) is an economic development investment agency dedicated to supporting the growth and development of the life sciences in Massachusetts, home to the most verdant and productive life sciences ecosystem in the world. Through public-private funding initiatives, the MLSC supports innovation, research and development, commercialization, and manufacturing activities in the fields of biopharma, medical device, diagnostics and digital health. Since its creation in 2007, the MLSC has strategically deployed approximately $1 billion in Massachusetts, through a combination of grants, loans, capital infrastructure investments, tax incentives and workforce programs. These investments have created thousands of jobs and propelled the development of new therapies, devices, and scientific advancements that are improving patient health and well-being in Massachusetts and beyond.
###
